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Bioanalytical methods play important role during development of new drugs. This is because 
determining the concentration of the drug of interest in biological matrices can help to reveal 
its mechanism of action, determine the values of basic pharmacokinetic parameters or study the 
fate of a potential drug during in vitro experiments. Considering the complexity of biological 
samples and low concentrations of studied compounds, the sample preparation prior to analysis 
is really important. Miniaturized techniques derived from standard extraction methods have 
significant presence in modern bioanalysis, mainly because they decrease both required sample 
volume and consumption of laboratory material to a minimum, and they enable automatization. 
One of the main areas of drug discovery is currently the treatment of cancer. Unfortunately, 
development of highly efficacious drugs and prolongation of patient survival have resulted in 
the risk of developing late complications associated with anticancer treatment including serious 
side effect such as damage of the heart after anthracycline administration, leading in some cases 
to heart failure. 
Experimental work of this thesis consists of 2 sections focused on bioanalytical evaluation of 
1) selected anticancer agents and 2) potential cardioprotectants. 
In the first part solid-phase microextraction is utilized as an alternative method for 
determination of plasma protein binding of thiosemicarbazone DpC. The suitability of the 
optimized protocol was verified by evaluating repeatability, linearity, and recovery of 
extraction from PBS buffer or plasma. The results of in vitro assay showed that DpC is highly 
bound to plasma proteins, which corresponds to the values previously published for other 
thiosemicarbazone Dp44mT. 
Next part is focused on development of rapid UHPLC-MS method for determination of 
anthracycline daunorubicin (DAU) and its metabolite in various biological matrices, enabling 
in vitro study of the fate of DAU during incubation with NO-donor – molsidomine, more 
precisely its active form SIN-1. It was observed that SIN-1 at higher concentrations accelerates 
the degradation of DAU, which is most likely to be the cause of unexpectedly low cytotoxicity 
of DAU in incubations with both cardiac and tumour cells. 
The aim of the third part of this work was to develop first UHPLC-MS method suitable for 
simultaneous determination of prodrug sobuzoxan, its active form (ICRF-154) and metabolite 
(EDTA-diamide) in biological samples. Based on the subsequent analysis of samples from the 
in vitro evaluation of sobuzoxan activation and metabolism, several important conclusions were 
drawn. 1) It gradually degrades in the cell culture medium; 2) readily penetrates into cardiac 
cells, where it is actively metabolized to ICRF-154 and EDTA-diamide and 3) it is rapidly 
decomposed in plasma. 
Furthermore, several simple chromatographic methods with UV detection have been developed 
to compare the stability of a number of newly synthesized aroylhydrazone analogues. 
Surprisingly, it has been shown that substitution of a salicylaldehyde group with 2,6-
dihydroxybenzaldehyde does not significantly increase stability of hydrazone bond. The most 
stable analogue (compound 5) was subsequently tested to determine its ability of chelating and 
protection of cardiac cells against the oxidative stress induced by various pro-oxidants. 
 
